Last checked at 28 May 2020 07:00
28 May 2020
Ā
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Ā
Covid-19 Project Update
Ā
Further to the Company's announcement on 16 April 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing NuvecĀ®, a novel delivery system for cancer treatments and vaccines,Ā is pleased to provide an update on the progress of its Covid-19 proof of concept work for NuvecĀ®.
As previously announced, the Company appointed Evotec International Gmbh ("Evotec") to undertake the NuvecĀ® proof of concept work. The Company can confirm that the first phase of the project has been carried out, within the expected timeframe, and that the plasmid DNA has been successfully amplified to produce sufficient material for the rest of the project and has been tested to confirm it matches the required specification. EvotecĀ has also used this batch of the plasmid DNA to express the Covid-19 spike protein to be used as a positive control for the studies. Evotec will now move to the second phase of the work and start the in-vitro testing of NuvecĀ® as planned, during the first week of June 2020. This phase is expected to last approximately ten weeks.
The third phase of the in-vivo protein expression testing will be to undertake an initial pre in-vivo study to demonstrate expression of the spike protein in target cells in a murine target. Following the recent fundraise, announced on 13 May 2020, the Company is now also exploring ways in which it can bring forward the start of certain areas of this third phase to run alongside the in-vitro work.
Ā
Enquiries:
Ā
N4 Pharma Plc Nigel Theobald, CEO Ā | Ā Via Scott PR |
Allenby Capital Limited James Reeve/Asha ChotaiĀ | Tel: +44(0)203 328 5656 |
Turner Pope Investments (TPI) Ltd Andrew Thacker | Tel: +44(0)20 3657 0050 |
Scott PR Georgia Smith Ā | Tel: +44(0)1477 539 539 |
Ā
About N4 Pharma
Ā
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called NuvecĀ®.
Ā
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use NuvecĀ® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.